Home » Trillium Therapeutics’ TTI-621 Acquires FDA Clearance
Trillium Therapeutics’ TTI-621 Acquires FDA Clearance
The FDA has given Trillium Therapeutics clearance to initiate a Phase 1 clinical trial of its lead drug candidate, TTI-621, to treat solid tumors and mycosis fungoides.
TTI-621 will be delivered by intratumoral injection in patients with relapsed and refractory, percutaneously accessible cancers.
This drug is designed as a checkpoint inhibitor of the innate immune system.
Upcoming Events
-
07May
-
14May
-
23May
-
30May
-
20Jun
-
21Oct